We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Introduction
Sincalide is a brain and intestinal skin with a variety of physiological effects. It is widely distributed in the central and peripheral nervous systems in addition to the presence of the gastrointestinal tract. Intravenous injection of sincalide has selective excitatory effects on the suprachic nucleus of rat hypothalamic nucleus; peripheral injection and lateral ventricle injection of sincalide have inhibitory effects on intragastric pressure (IGP) and gastric peristalsis frequency (GMF). Sincalide has a central regulatory effect on neuroendocrine and gastrointestinal functions.
Pharmacologic action
Cholecystokinin receptor type A (CCK-A) blocker devazepide was injected into the hippocampus and found no significant effect on IGF and GMF, indicating that sincalide in the hippocampus has no neuropathic effect on gastric motion. However, it has also been reported that CCK-A receptor blockers enhance gastric motility. Interpretation of the results of such contradictions is generally considered to be the effect of other factors, such as dose, animal lineage, duration of action, and hunger. After injection of devazepide, the aforementioned inhibition no longer occurs. It can be considered that the CCK-A receptor is blocked, that is, the inhibition of gastric activity by Sincalide is achieved by activating the CCK-A receptor.
Function
It is reported in the literature that the hippocampus is rich in sincalide and dense sincalide receptors, and sincalide activity in the hippocampus is associated with multiple functional activities (such as visceral activities, emotions, etc.). The study found that sincalide activity in the central nervous system can inhibit gastric motility, and this inhibition is achieved by the amygdala through the CCK-A receptor. Microinjection of sincalide was found to significantly inhibit IGP and GMF, suggesting that an increase in the sincalide content in the hippocampus may regulate gastric motion.
Pharmacokinetics and metabolism
The bilateral hippocampal CA3 (coordinates are AP3.3, L and R2.5, H3.8) was positioned and microinjected by 1 microliter, and the injection was completed in 15 seconds with a micropropeller. After injection of sincalide, IGP and GMF decreased, and the difference was significant compared with that before injection.
References:
1. Su Hailing, Li Chunlin. Effects of microinjection of cholecystokinin and its receptor blockers on intragastric pressure and gastric motility in rat hippocampus. ACTA ACADEMIAE MEDICINAE QINGDAO. Vol 31,No,1
2. Tang M, MeCann MJ, Renaud LP, et al.Seleetive excitation of rat supraoptic nuecleus oxytocin-secreting neurons after administration of CCK -8 and gastric distension. Soc Neurosci Abstr, 1986; 12 : 447.
3. Li Chunlin, Su Hailing. The role of hypothalamic ventromedial nucleus in the inhibition of gastric motility by amygdala. ACTA ACADEMIAE MEDICINAE QINGDAO. Vol 31,No,2.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com